YD Bio Ltd YDES
Medical Specialities · data as of November 13, 2026
YD Bio Ltd (YDES) is a healthcare company listed in the US with a market value of about $346M. In the twelve months to June 30, 2026 it had revenue of $1M and net income of $305762, a net margin of 24.7%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%.
About YD Bio
YD Bio is listed in the US and classified in medical specialities. It was profitable in 1 of the last 3 years in our data. It spends 268% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $1M | $596817 | $510360 | $350131 |
| Net income | $305762 | -$8M | -$1M | $13560 |
| Free cash flow | -$9M | -$8M | -$1M | -$55947 |
| EPS (diluted) | $0.00 | $-0.12 | $-0.02 | $0.00 |
| Net margin | 24.7% | -1392.6% | -276.6% | 3.9% |
| ROIC | — | — | -17.5% | -32.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does YD Bio pay a dividend?
Not currently.
Is YD Bio a good stock to buy?
We do not give buy or sell advice. YD Bio scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.